Clinical Trials
5 trialsNCT06324240 2026-01-26
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
Phase 1 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02892734 2020-07-16
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Northwestern University
Phase 2 Terminated
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT00060372 2013-03-27
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
National Cancer Institute (NCI)
Phase 1 Completed